OnePin Peptide Library · Growth Hormone

Growth Hormone Growth Hormone Secretagogue Blend Not FDA-approved · investigational

CJC-1295 no DAC / Hexarelin Blend

CJC + Hexarelin

Growth Hormone Secretagogue BlendGHRH + Most Potent GHRP CombinationMaximum GH output blend29-Amino Acid Analog + Cardioprotective Hexapeptide

CJC-1295 no DAC / Hexarelin Blend is a pre-mixed growth hormone secretagogue combination that pairs Modified GRF(1-29) with the most potent GHRP available. Hexarelin (Examorelin) produces the highest raw GH release per dose of any ghrelin receptor agonist, making this blend the strongest GH-releasing peptide combination on the market. It is designed for short, intensive cycles where maximum GH output is the priority.

Quick Start

Route

Subcutaneous (SubQ) injection

Start low

100mcg CJC + 100mcg Hexarelin per injection

Frequency

1-2x daily

Timing

Fasted. Minimum 2 hours empty stomach. No eating for 30 min post-injection. Strict fasting compliance is critical for maximum GH output.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Quick Start

Conservative start

100mcg CJC + 100mcg Hexarelin per injection · Subcutaneous (SubQ) injection · 1-2x daily

Lowest starting point. Hold about a week to assess tolerance before stepping up.

100mcg CJC + 100mcg Hexarelin per injection

1-2x daily

Expert

Maximal Pulse (Cycled)

~200 mcg total (100/100) · SubQ · Daily

anecdotal · community

~200 mcg total (100/100)

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Target dose

050100u

Draw to

— units

◆

How it works

This blend delivers the most potent dual-receptor GH stimulation available through injectable secretagogues:

CJC-1295 no DAC (Mod GRF 1-29)

Binds GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA signaling cascade to prime and release stored GH granules. The four amino acid substitutions protect against DPP-IV degradation, extending the half-life to approximately 30 minutes. Produces acute GH pulses preserving natural pulsatile patterns.

Hexarelin

Binds GHS-R1a (ghrelin receptor) with the highest efficacy of any GHRP, triggering GH release through the PLC/IP3/PKC pathway. Hexarelin's strong receptor activation produces the most potent GH pulses but also causes the fastest receptor desensitization (tachyphylaxis), limiting effective cycle length to 4-8 weeks. It also suppresses somatostatin release more aggressively than other GHRPs.

Cardioprotective Mechanism

Uniquely among GHRPs, Hexarelin binds CD36 scavenger receptors on cardiomyocytes, activating cardioprotective signaling pathways independent of GH release. This includes improved cardiac contractility, reduced fibrosis, and protection against ischemia-reperfusion injury.

Synergistic Amplification

The GHRH signal (CJC) and the strongest GHRP signal (Hexarelin) converge through independent intracellular pathways, producing GH pulses 5-8x above baseline in responsive individuals. This exceeds the output of CJC/Ipa or CJC/GHRP-2 combinations.

Hormonal Trade-offs

Hexarelin elevates cortisol and prolactin more than GHRP-2, which elevates more than Ipamorelin. These elevations are dose-dependent and generally manageable at standard doses but require monitoring during cycles.

What to expect

Early

Days 1–7

Days 1-7: Strong flushing and tingling post-injection (Hexarelin's potent GHS-R1a activation). Improved sleep quality with deeper slow-wave phases. Moderate appetite increase. Possible mild water retention. The flush intensity is a useful biomarker - when it diminishes, the receptor is desensitizing.

Mid

Weeks 2–4

Weeks 2-4: Peak GH output period. Body composition changes visible faster than with milder blends. Skin quality improving. Recovery from training dramatically enhanced. Fat loss and lean mass changes measurable. This is the most productive window of the cycle.

Later

Weeks 4–12

Weeks 4-8: Receptor desensitization begins in most individuals. Flush response weakens. GH output gradually declines toward baseline. End the cycle when the flush response is notably reduced. Take a 4-8 week break before starting another Hexarelin cycle. Consider transitioning to CJC/Ipa for maintenance between Hexarelin cycles.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

1994Growth hormone-releasing activity of hexarelin in humans. A dose-response study · Imbimbo BP et al, European Journal of Clinical Pharmacology ↗peer reviewed

1996The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity · Rahim A et al, Clinical Endocrinology ↗peer reviewed

1995The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects · Loche S et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed

2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · Teichman SL et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed

The honest take

◆

Produces the highest GH release of any injectable secretagogue combination

Supported by human data. Hexarelin produces the largest GH pulse of any GHRP, and dual GHRH+GHRP stimulation is synergistic. However, this potency comes with faster receptor desensitization and more hormonal side effects than milder combinations.

Hexarelin provides direct cardioprotection independent of GH release

Supported by human cardiac studies and animal models. CD36 receptor binding on cardiomyocytes is a well-characterized mechanism unique to Hexarelin among GHRPs. Clinical relevance for healthy individuals using short peptide cycles is less established.

GH pulses reach 5-8x above baseline

Plausible

Plausible based on human GH stimulation data from individual components. The combined synergistic output has not been precisely quantified in controlled trials for this specific blend ratio.

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

AOD-9604No interaction. GH fragment peptide works through different pathway. Safe in same syringe.

GHK-CuCompatible for stacking. Draw GHK-Cu LAST due to copper. High GH enhances collagen remodeling.

MOTS-cMitochondrial peptide with independent mechanism. Safe in same syringe.

SelankNo reactive residue conflicts. Safe in same syringe.

Keep separate

CJC-1295 with DACDAC version provides continuous GH elevation that disrupts pulsatile signaling. Do not combine sustained and pulsatile GHRH analogs.

Somatostatin analogs (Octreotide)Directly antagonizes GH release. Completely negates the purpose of this blend.

High-dose insulinElevated insulin blunts GH response. Fasted state is required for optimal GH release from this blend.

NAD+Acidic pH of NAD+ can denature peptides. Different route anyway (NAD+ is typically IM or IV).

Side effects & safety

Commonly reported

Intense flushing and warmth post-injection (stronger than other GHRPs)
Tingling, head rush, or dizziness immediately after injection
Moderate appetite stimulation (between Ipamorelin and GHRP-6)
Water retention in first 1-2 weeks
Vivid dreams and altered sleep patterns

Less common & notes

Hexarelin elevates cortisol and prolactin more than other GHRPs.
At doses above 200mcg, cortisol elevation may cause post-injection anxiety or irritability.
Elevated prolactin can cause nipple sensitivity or mild gynecomastia in susceptible individuals during extended use - this is one reason cycles should be kept to 4-8 weeks.
Some users experience post-injection lethargy from the strong GH pulse.
Receptor desensitization (tachyphylaxis) is the primary limitation - extending cycles beyond 8 weeks produces diminishing returns and delays recovery of receptor sensitivity.

Pharmacokinetics

Illustrative plasma concentration · 24 h

Half-life

CJC-1295 no DAC: ~30 min; Hexarelin: ~70 min. Combined GH pulse duration: 1.5-2.5 hours.

Peak · Tmax

CJC: 15-30 min; Hexarelin: 15-20 min. Peak synergistic GH release at ~20-30 min post-injection.

Elimination

CJC cleared within 2-3 hours. Hexarelin cleared within 4-5 hours. GH pulse elevation returns to baseline by 3-4 hours.

Activity

GH pulse lasts 1.5-2.5 hours (slightly longer than CJC/Ipa due to Hexarelin potency). Downstream IGF-1 elevation persists 12-20 hours. Hexarelin CD36 cardiac effects have a separate, longer duration independent of GH pulse.

Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8 degrees C. Use within 28-30 days of reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if solution becomes cloudy or contains particulate matter.

Regulatory status

Not FDA-approved as a combination product. Available through compounding pharmacies with prescription. CJC-1295 no DAC (Mod GRF 1-29) has published human pharmacokinetic data. Hexarelin (Examorelin) has been studied in multiple human clinical trials for GH release and cardiac applications, and is approved in some countries for diagnostic use. Pre-mixed blends are a compounding pharmacy product. Classified as research peptides in most jurisdictions. All use is experimental and off-label.

Put it to work

Calculate, log & track

Open CJC-1295 no DAC / Hexarelin Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open CJC-1295 no DAC / Hexarelin Blend in the app →

Go deeper

The guide & community

The complete CJC-1295 no DAC / Hexarelin Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community